1. European Medicines Agency, Heads of Medicines Agencies. Guideline on good pharmacovigilance practice. Module V—risk management systems. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf . Accessed 19 Jul 2013.
2. Zomerdijk IM, Sayed-Tabatabaei FA, Trifiro G, Blackburn SC, Sturkenboom MC, Straus SM. Risk minimization activities of centrally authorized products in the EU: a descriptive study. Drug Saf. 2012;35(4):299–314.
3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: pharmacovigilance planning E2E. 2004. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2E/Step4/E2E_Guideline.pdf . Accessed 19 Jul 2013.
4. Food and Drug Administration. Guidance for industry: format and content of proposed risk evaluation and mitigation strategies (REMS), REMS assessments, and proposed REMS modifications. Draft guidance. 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM184128.pdf . Accessed 19 Jul 2013.
5. Raine J, Wise L, Blackburn S, Eichler HG, Breckenridge A. European perspective on risk management and drug safety. Clin Pharmacol Ther. 2011;89(5):650–4.